The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Tufts Medical Center and New England Cancer Specialists form affiliation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

TUFTS MEDICAL CENTER and New England Cancer Specialists formed a clinical affiliation to expand patients’ access to care, clinical trials, and survivorship resources. NECS is the largest provider of cancer services in Maine, with nearly 45,000 patient visits in 2015 at locations in Scarborough, Brunswick and Kennebunk. Through the affiliation agreement, Tufts MC will be...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account